Fig. 3: CoVac-1-induced T-cell responses.
From: Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
CoVac-1-induced T-cell responses assessed ex vivo by IFN-γ ELISPOT assays using PBMCs from (a) Phase I, (b) Phase II, (c) Phase I/II combined study patients (n = as indicated) collected before administration (day 1) and at different time points after administration (day 7, day 14, day 28). No. (ind) indicates the number of analyzed patients with the number of patients showing a CoVac-1-induced T-cell response (spot count post vaccination ≥2-fold higher than the respective spot count on day 1) in brackets. Median (pos) represents the median intensity of T-cell responses with the median of positive T-cell responses in brackets (≥3-fold higher than the negative control). % response indicates the percentage of study patients showing CoVac-1-induced T-cell responses. Two-sided Wilcoxon signed-rank test. d Number of CoVac-1 peptides for which patients without and with CoVac-1-induced T-cell responses at day 28 after CoVac-1 application possess matching HLA-DR alleles. Two-sided Mann-Whitney U test. e The number of CoVac-1 T-cell epitopes (n = 6) per patient (n = as indicated) that elicited a vaccine-induced T-cell response. Two-sided Wilcoxon signed-rank test. (a, d) The intensity of T-cell responses is depicted as calculated spot counts (mean spot count of technical replicates minus the respective negative control). (a–e) Box plots show median with 25th or 75th percentiles, and min/max whiskers. no., number; pos, positive; ind, induced.
